Biotech research and therapeutics by Rigel Pharmaceuticals

Rigel Pharmaceuticals announced that CEO Raul Rodriguez will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 8:45am ET in New York. Investors and ...

Rigel Pharmaceuticals announced its participation in the ASCO Annual Meeting, aiming to connect with oncology professionals and industry peers. The company encouraged attendees to visit their ...

Rigel Pharmaceuticals announced that its partner Kissei has submitted a New Drug Application (NDA) in Japan for olutasidenib, aimed at treating relapsed or refractory acute myeloid leukemia (AML) ...

Rigel Pharmaceuticals has announced an exclusive global license agreement to develop, manufacture, and commercialize VEPPANU (vepdegestrant). The move positions Rigel Pharmaceuticals to further ...

Rigel Pharmaceuticals today announced it has entered into an exclusive, global license agreement to develop, manufacture and commercialize VEPPANU, also known as vepdegestrant. The company plans ...

Rigel Pharmaceuticals will release its financial results for the first quarter of 2026 and provide a business update on May 5. Investors and analysts await insights into the company’s ...

Rigel Pharmaceuticals has announced new presentations highlighting advancements in its hematology and oncology portfolio at the American Society of Hematology 2025 (ASH25) conference. These ...

Rigel Pharmaceuticals CEO, Raul Rodriguez, took center stage in a recent interview with Brian Sullivan, host of CNBC’s Power Lunch. In San Francisco, Rodriguez articulated Rigel's strategic ...

Rigel Pharmaceuticals is focusing attention on October 25th as MDS World Awareness Day to highlight the importance of research in myelodysplastic syndromes (MDS), a group of rare blood cancers. ...